title: [Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture].
abstract: METHODS
  A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C(3)F(8) and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin(®) injection to be inactivated, after one year of follow-up.
authors: Servicio de Oftalmología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. xvalldeperas@gmail.com
authors: X
authors: X
authors: Valldeperas
authors: R
authors: R
authors: Bonilla
authors: M R
authors: MR
authors: Romano
authors: J
authors: J
authors: de la Cámara
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D016570:Bruch Membrane / Q000293:injuries; D002829:Choroid / Q000293:injuries*; D002832:Choroid Hemorrhage / Q000209:etiology; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005466:Fluorocarbons / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007103:Immobilization; D058449:Intravitreal Injections; D008297:Male; D012421:Rupture / Q000150:complications; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D014949:Wounds, Nonpenetrating / Q000150:complications
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005466:Fluorocarbons; D000068258:Bevacizumab; C042852:perflutren; D010959:Tissue Plasminogen Activator